Skip to main content

Advertisement

SpringerLink
Log in

Survivorship in untreated breast cancer patients

  • Review Article
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

In any disease, the knowledge of the natural history of untreated cases provides a real background against which the real advantages of a new treatment itself are judged. Fortunately, in the present days, there are scant data on outcomes in patients with untreated breast cancer. In an attempt to provide this background against which the virtues of current curative and palliative treatments can be more accurately assessed, we have reviewed the literature regarding published untreated breast cancer series. Taking into consideration all the difficulties of analyzing reports written on the last half of the nineteenth century or on the first half of the twentieth century, in most reports, patients survived almost 3–4 years without any type of treatment. Worth mentioning, approximately 5–10 % of untreated patients lived longer than 10 years. Thus, the spectrum of clinical aggressiveness of untreated breast cancer varies between virulence and chronic disease. These facts should be taken into account when considering the value of current treatments for early-stage disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432–44.

    Article  CAS  PubMed  Google Scholar 

  2. Rachet B, Maringe C, Nur U, Quaresma M, Shah A, Woods LM, et al. Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. Lancet Oncol. 2009;10(4):351–69.

    Article  PubMed  Google Scholar 

  3. Brinkley D, Haybittle JL. The curability of breast cancer. World J Surg. 1977;1(3):287–9.

    Article  CAS  PubMed  Google Scholar 

  4. Brinkley D, Haybrittle JL. The curability of breast cancer. Lancet. 1975;2(7925):95–7.

    Article  CAS  PubMed  Google Scholar 

  5. Duncan W, Kerr GR. The curability of breast cancer. Br Med J. 1976;2(6039):781–3.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Easson EC, Russell MH. The curability of cancer in various sites. London: Pittman Inc; 1968.

    Google Scholar 

  7. Pocock SJ, Gore SM, Kerr GR. Long term survival analysis: the curability of breast cancer. Stat Med. 1982;1(2):93–104.

    Article  CAS  PubMed  Google Scholar 

  8. Cade S. Discussion on carcinoma of breast. Br J Radiol. 1948;21(252):596–9.

    Article  CAS  PubMed  Google Scholar 

  9. Cade S. Carcinoma of the breast. J Am Med Assoc. 1948;138(15):1083–7.

    Article  CAS  PubMed  Google Scholar 

  10. Cade S. Modern treatment of carcinoma of the breast. Med Press. 1948;219(20):435–8.

    CAS  PubMed  Google Scholar 

  11. Bloom HJG. The natural history of untreated breast cancer. Ann N Y Acad Sci. 1964;114(1):747–54.

    Google Scholar 

  12. Bloom HJG, Richardson WW, Harries EJ. Natural history of untreated breast cancer (1805–1933). Comparison of untreated and treated cases according to histological grade of malignancy. Br Med J. 1962;2(5299):213–21.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Wade P. Untreated carcinoma of the breast. Br J Radiol. 1946;19(1):272–80.

    Article  CAS  PubMed  Google Scholar 

  14. Gross SW. A practical treatise of tumours of the mammary gland. New York: Appelton & Co; 1880.

    Google Scholar 

  15. Lazarus-Barlow WS, Leeming JH. The natural duration of cancer. Br Med J. 1924;2(3320):266–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Greenwood M. A report on the natural duration of cancer: reports on public health andmedical subjects. London: H.M.S.O; 1926.

    Google Scholar 

  17. Daland EM. Untreated carcinoma of the breast. Surg Gynecol Obstet. 1927;44(1):264–8.

    Google Scholar 

  18. Forber JE. Report of public health medical subjects. London: H.M.S.O; 1931 1931.

    Google Scholar 

  19. MacKay EN, Sellers AH. Breast cancer at the Ontario Cancer Clinics, 1938–1956. A statistical review. Ontario: Medical statistics branch, Ontario department of health; 1965.

    Google Scholar 

  20. Wyard S. The natural duration of cancer. Br Med J. 1925;1(3344):206–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Gross SW, Boenning HC. Some points in the life and diagnosis of carcinoma of the mammary gland, based upon a study of one hundred cases. Boston Med Surg J. 1880;102(1):289–93.

    Article  Google Scholar 

  22. Nathanson IT, Welch CE. Life expectancy and incidence of malignant disease: carcinoma of the breast. Am J Cancer. 1936;28(1):40–53.

    Google Scholar 

  23. Phillips AJ. A comparison of treated and untreated cases of cancer of the breast. Br J Cancer. 1959;13(1):20–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Baum M, Demicheli R, Hrushesky W, Retsky M. Does surgery unfavourably perturb the “natural history” of early breast cancer by accelerating the appearance of distant metastases? Eur J Cancer. 2005;41(4):508–15.

    Article  PubMed  Google Scholar 

  25. Johnstone PA, Norton MS, Riffenburgh RH. Survival of patients with untreated breast cancer. J Surg Oncol. 2000;73(4):273–7.

    Article  CAS  PubMed  Google Scholar 

  26. Verkooijen HM, Fioretta GM, Rapiti E, Bonnefoi H, Vlastos G, Kurtz J, et al. Patients’ refusal of surgery strongly impairs breast cancer survival. Ann Surg. 2005;242(2):276–80.

    Article  PubMed Central  PubMed  Google Scholar 

  27. Chang EY, Glissmeyer M, Tonnes S, Hudson T, Johnson N. Outcomes of breast cancer in patients who use alternative therapies as primary treatment. Am J Surg. 2006;192(4):471–3.

    Article  PubMed  Google Scholar 

  28. Han E, Johnson N, DelaMelena T, Glissmeyer M, Steinbock K. Alternative therapy used as primary treatment for breast cancer negatively impacts outcomes. Ann Surg Oncol. 2011;18(4):912–6.

    Article  PubMed  Google Scholar 

  29. Joseph K, Vrouwe S, Kamruzzaman A, Balbaid A, Fenton D, Berendt R, et al. Outcome analysis of breast cancer patients who declined evidence-based treatment. World J Surg Oncol. 2012;10(1):118.

    Article  PubMed Central  PubMed  Google Scholar 

  30. Demicheli R, Retsky MW, Hrushesky WJ, Baum M. Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures. Nat Clin Pract Oncol. 2007;4(12):699–710.

    Article  PubMed  Google Scholar 

  31. Demicheli R, Valagussa P, Bonadonna G. Double-peaked time distribution of mortality for breast cancer patients undergoing mastectomy. Breast Cancer Res Treat. 2002;75(2):127–34.

    Article  CAS  PubMed  Google Scholar 

  32. Galmarini CM, Tredan O, Galmarini FC. Concomitant resistance and early-breast cancer: should we change treatment strategies? Cancer Metastasis Rev. 2014;33(1):271–83.

    Article  PubMed  Google Scholar 

  33. Ambs S. Prognostic significance of subtype classification for short- and long-term survival in breast cancer: survival time holds the key. PLoS Med. 2010;7(5):e1000281.

    Article  PubMed Central  PubMed  Google Scholar 

  34. Karrison TG, Ferguson DJ, Meier P. Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst. 1999;91(1):80–5.

    Article  CAS  PubMed  Google Scholar 

  35. Jerez JM, Franco L, Alba E, Llombart-Cussac A, Lluch A, Ribelles N, et al. Improvement of breast cancer relapse prediction in high risk intervals using artificial neural networks. Breast Cancer Res Treat. 2005;94(3):265–72.

    Article  CAS  PubMed  Google Scholar 

  36. Sant M, Gatta G, Micheli A, Verdecchia A, Capocaccia R, Crosignani P, et al. Survival and age at diagnosis of breast cancer in a population-based cancer registry. Eur J Cancer. 1991;27(8):981–4.

    Article  CAS  PubMed  Google Scholar 

  37. Baum M, Badwe RA. Does surgery influence the natural history of breast cancer? In: Wise H, Johnson HJ, editors. Breast cancer: controversies in management. Armonk, NY: Futura; 1994. p. 61–9.

    Google Scholar 

  38. Yakovlev AY, Tsodikov AD, Boucher K, Kerber R. The shape of the hazard function in breast carcinoma: curability of the disease revisited. Cancer. 1999;85(8):1789–98.

    Article  CAS  PubMed  Google Scholar 

  39. Gao F, Tan SB, Machin D, Wong NS. Confirmation of double-peaked time distribution of mortality among Asian breast cancer patients in a population-based study. Breast Cancer Res. 2007;9(2):R21.

    Article  PubMed Central  PubMed  Google Scholar 

  40. Mc KN. Control of cancer mortality. Lancet. 1954;266(6805):251–4.

    Google Scholar 

  41. Fox MS. On the diagnosis and treatment of breast cancer. JAMA. 1979;241(5):489–94.

    Article  CAS  PubMed  Google Scholar 

  42. Vorherr H. Pathobiology of breast cancer: hypothesis of biological predetermination and long-term survival. Klin Wochenschr. 1981;59(15):819–29.

    Article  CAS  PubMed  Google Scholar 

  43. Ruggiero RA, Bruzzo J, Chiarella P, Bustuoabad OD, Meiss RP, Pasqualini CD. Concomitant tumor resistance: the role of tyrosine isomers in the mechanisms of metastases control. Cancer Res. 2012;72(5):1043–50.

    Article  CAS  PubMed  Google Scholar 

  44. Galmarini D, Galmarini CM, Galmarini FC. Cancer chemotherapy: a critical analysis of its 60 years of history. Crit Rev Oncol Hematol. 2012;84(2):181–99.

    Article  PubMed  Google Scholar 

  45. Retsky M, Demicheli R, Hrushesky WJ. Does surgery induce angiogenesis in breast cancer? Indirect evidence from relapse pattern and mammography paradox. Int J Surg. 2005;3(3):179–87.

    Article  PubMed  Google Scholar 

  46. Retsky M, Rogers R, Demicheli R, Hrushesky WJ, Gukas I, Vaidya JS, et al. NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup. Breast Cancer Res Treat. 2012;134(2):881–8.

    Article  CAS  PubMed  Google Scholar 

  47. Adair F, Berg J, Joubert L, Robbins GF. Long-term followup of breast cancer patients: the 30-year report. Cancer. 1974;33(4):1145–50.

    Article  CAS  PubMed  Google Scholar 

  48. Campos JL. Observations on the mortality from carcinoma of the breast. Br J Radiol. 1972;45(529):31–8.

    Article  CAS  PubMed  Google Scholar 

  49. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14(8):2197–205.

    CAS  PubMed  Google Scholar 

  50. Brinkley D, Haybittle JL. A 15-year follow-up study of patients treated for carcinoma of the breast. Br J Radiol. 1968;41(483):215–21.

    Article  CAS  PubMed  Google Scholar 

  51. Brinkley D, Haybittle JL. Long-term survival of women with breast cancer. Lancet. 1984;1(8386):1118.

    Article  CAS  PubMed  Google Scholar 

  52. Moskowitz M. Screening for breast cancer. JAMA. 1977;238(3):213.

    Article  CAS  PubMed  Google Scholar 

  53. Guth U, Huang DJ, Dirnhofer S, Rochlitz C, Wight E. Distant metastatic breast cancer as an incurable disease: a tenet with a need for revision. Cancer J. 2009;15(1):81–6.

    Article  PubMed  Google Scholar 

  54. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010;7(5):e1000279.

    Article  PubMed Central  PubMed  Google Scholar 

  55. Yardley DA, Tripathy D, Brufsky AM, Rugo HS, Kaufman PA, Mayer M, et al. Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. Br J Cancer. 2014;110(11):2756–64.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  56. Koch L, Jansen L, Herrmann A, Stegmaier C, Holleczek B, Singer S, et al. Quality of life in long-term breast cancer survivors—a 10-year longitudinal population-based study. Acta Oncol. 2013;52(6):1119–28.

    Article  PubMed  Google Scholar 

  57. Ali HR, Provenzano E, Dawson SJ, Blows FM, Liu B, Shah M, et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol. 2014;25(8):1536–43.

    Article  CAS  PubMed  Google Scholar 

  58. Jordan VC, Ford LG. Paradoxical clinical effect of estrogen on breast cancer risk: a “new” biology of estrogen-induced apoptosis. Cancer Prev Res (Phila). 2011;4(5):633–7.

    Article  CAS  Google Scholar 

  59. LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011;305(13):1305–14.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  60. Demicheli R, Abbattista A, Miceli R, Valagussa P, Bonadonna G. Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res Treat. 1996;41(2):177–85.

    Article  CAS  PubMed  Google Scholar 

  61. Demicheli R, Miceli R, Moliterni A, Zambetti M, Hrushesky WJ, Retsky MW, et al. Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. Ann Oncol. 2005;16(9):1449–57.

    Article  CAS  PubMed  Google Scholar 

  62. Demicheli R, Valagussa P, Bonadonna G. Does surgery modify growth kinetics of breast cancer micrometastases? Br J Cancer. 2001;85(4):490–2.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Conflict of interest

Carlos M. Galmarini is currently an employee and stockowner of PharmaMar. Olivier Tredan and Felipe C. Galmarini declare no conflict of interest.

Author information

Author notes

  1. Carlos M. Galmarini

    Present address: PharmaMar S.A.U., Avda de los Reyes 1 (Pol Ind La Mina), 28770, Colmenar Viejo, Madrid, Spain

Authors and Affiliations

  1. Fundación Marcel Dargent - Escuela Sudamericana de Oncología, Montevideo 1686, CP1021, Ciudad Autónoma de Buenos Aires (CABA), Argentina

    Carlos M. Galmarini & Felipe C. Galmarini

  2. Département de Cancérologie Médicale, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, 69373, Lyon, France

    Olivier Tredan

Authors
  1. Carlos M. Galmarini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olivier Tredan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Felipe C. Galmarini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carlos M. Galmarini.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Galmarini, C.M., Tredan, O. & Galmarini, F.C. Survivorship in untreated breast cancer patients. Med Oncol 32, 29 (2015). https://doi.org/10.1007/s12032-014-0466-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0466-x

Keywords

Search

Navigation